Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction

New England Journal of Medicine

Volumn 334, Issue 14, 1996, Pages 873-877

  Linet, Otto I ^a   Ogrinc, Francis G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORPUS CAVERNOSUM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FIBROSIS; HEMATOMA; HUMAN; IMPOTENCE; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; PAIN; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ALPROSTADIL; COITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; INJECTIONS; MALE; MIDDLE AGED; PAIN; PENIS; PROSPECTIVE STUDIES; SELF ADMINISTRATION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0029919229     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199604043341401     Document Type: Article

References (26)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83-90
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinley JB Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
3. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321:1648-59.
4. Lue TF. Intracavernous drug administration: its role in diagnosis and treatment of impotence. Semin Urol 1990;8:100-6.
5. Kim N, Azadzoi KM, Goldstein I, de Tejada IS. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle J Clin invest 1991,88:112-8.
6. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326.90-4.
7. 1 for organic impotence. Nippon Hinyokika Gakkai Zasshi 1986,77:954-62 (In Japanese)
8. 1 on penile erection and erectile failure. J Urol 1987,137.1010
9. 1 in impotent men. J Urol 1988;140:66-8.
10. 1 bei erektiler Dysfunktion. Urologe A 1989;28:94-8
11. Berry DA. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, 1990:402-8.
12. Giesbers AAGM, Bruins JL, Kramer AEJL, Jenas U. New methods in the diagnosis of impotence: RigiScan penile tumescence and rigidity monitoring and diagnostic papaverine hydrochloride injection. World J Urol 1987;5:173-6.
13. Djamilian M, Stief CG, Hartmann U, Jonas U. Predictive value of real-time RigiScan monitoring for the etiology of organogenic impotence. J Urol 1993;149:1269-71.
14. 1 in erectile dysfunction. Br J Clin Pharmacol 1989,28:567-71.
15. von Heyden B, Donatucci CF, Marshall GA, Brock GB, Lue TF. A prostaglandin E1 dose-response study in man. J Urol 1993;150:1825-8
16. Junemann K-P, Alken P. Pharmacotherapy of erectile dysfunction a review. Int J Impot Res 1989;1:71-93.
17. 1 in erectile dysfunction Clin Invest 1994;72:139-49.
18. Earle CM, Keogh EJ, Ker JK, Cherry DJ, Tulloch AGS, Lord DJ. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Paraplegia 1992;30 273-6.
19. 1. J Urol 1991;146:786-9
20. Capetola RJ, Rosenthale ME, Dubinsky B, McGuire JL. Peripheral antialgesics: a review. J Clin Pharmacol 1983;23:545-56
21. Zentgraf M, Ludwig G, Ziegler M. How safe is the treatment of impotence with intracavernous autoinjection? Eur Urol 1989;16:165-71
22. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146 1007-9.
23. Amin Z, Patel U, Friedman EP, Vale JA, Kirby R, Lees WR. Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men. Br J Radiol 1993;66:398-402.
24. Chan JCK, Levenson S, Payton TR, Krane RJ, Goldstein I Five to seven year follow-up of patients in a pharmacologic erection program satisfaction and complications. J Urol 1992;147:Suppl 309A. abstract
25. Virag R, Nollet F, Greco E, Paris F. Local tolerance of papaverine-based medications for self intracavernons injections (SICI) J Urol 1994,151: Suppl:456A. abstract
26. Kolaja GJ, Kirton KT. Toxicology studies with alprostadil. In: Goldstein I, Lue TF, eds. The role of alprostadil in the diagnosis and treatment of erectile dysfunction. Princeton, N.J Excerpta Medica, 1993:40-50.